DR6 Stock Chart & Stats
€22.08
€0.25(1.15%)
At close: 4:00 PM EDT
€22.08
€0.25(1.15%)
Day’s Range― - ―
52-Week Range€17.52 - €23.02
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.84B
Enterprise Value€3.04K
Total Cash (Recent Filing)€851.46M
Total Debt (Recent Filing)€50.79M
Price to Earnings (P/E)11.6
Beta0.37
Next Earnings
Aug 04, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.23
Shares Outstanding171,235,870
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)3.69
Price to Sales (P/S)4.22
P/FCF Ratio43.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€28.74Price Target Upside30.16% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)0.34
Revenue Forecast (FY)€1.08B
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Cash RunwayACADIA’s very low leverage together with $851M cash provides durable financial flexibility to fund commercial expansion, upcoming Phase II/III readouts, and R&D without near-term refinancing risk. This supports multi-quarter execution on sales force buildout and trial timelines.
Sustained Revenue Recovery And High Gross MarginsThe company’s multi-year shift from losses to consistent profitability with strong revenue growth and very high gross margins indicates structural product economics. Durable gross margins mean incremental sales primarily flow to the bottom line, supporting long-term profitability if demand holds.
Commercial Momentum: NUPLAZID And DAYBUE Franchise ExpansionRobust uptake of DAYBUE (and early STIX adoption) alongside rising NUPLAZID demand, plus a material sales force expansion, indicates strengthening commercial capabilities and addressable reach. These durable commercial investments can scale revenue and support management’s multi‑year sales targets if adoption persists.
Bears Say
High Gross‑to‑net Discounts Reduce Realizable RevenueLarge gross‑to‑net deductions materially lower net product revenue and compress cash conversion of sales. Persistently elevated adjustments would reduce sustainable revenue per prescription and require higher volumes to maintain margins, increasing dependency on commercial scale and payer negotiations.
Operating Spend Jump And Uneven Cash ConversionA sizable SG&A step-up to fund commercialization increases fixed cost leverage and raises break‑even needs. Coupled with operating cash flow coverage below net income and historically choppy free cash flow, this creates execution risk: sustained sales growth is needed to absorb elevated operating spend without eroding cash reserves.
Regulatory And R&D Execution RisksAn ongoing European reexamination for trofinetide and an upcoming R&D leadership transition pose structural pipeline execution risks. Delays or adverse regulatory outcomes or leadership disruption could push back pivotal readouts, reduce near‑term upside, and increase development costs across multi‑phase programs.
ACADIA Pharmaceuticals News
DR6 FAQ
What was ACADIA Pharmaceuticals’s price range in the past 12 months?
ACADIA Pharmaceuticals lowest stock price was €17.52 and its highest was €23.02 in the past 12 months.
What is ACADIA Pharmaceuticals’s market cap?
ACADIA Pharmaceuticals’s market cap is €3.84B.
When is ACADIA Pharmaceuticals’s upcoming earnings report date?
ACADIA Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is today.
How were ACADIA Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is ACADIA Pharmaceuticals overvalued?
According to Wall Street analysts ACADIA Pharmaceuticals’s price is currently Undervalued.
Does ACADIA Pharmaceuticals pay dividends?
ACADIA Pharmaceuticals does not currently pay dividends.
What is ACADIA Pharmaceuticals’s EPS estimate?
ACADIA Pharmaceuticals’s EPS estimate is 0.05.
How many shares outstanding does ACADIA Pharmaceuticals have?
ACADIA Pharmaceuticals has 171,235,870 shares outstanding.
What happened to ACADIA Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ACADIA Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:DR6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ACADIA Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€28.74 (30.16% Upside)
€28.74 (30.16% Upside)
Blogger Sentiment
Bullish
DE:DR6 Sentiment 100%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.20%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
41.76%
Trailing 12-Months
Company Description
ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
DR6 Company Deck
DR6 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a predominantly positive commercial and pipeline picture: solid Q1 revenue growth (+11% adjusted), robust DAYBUE momentum (+20% YoY) and encouraging early uptake of the DAYBUE STIX formulation, continued demand and referral gains for NUPLAZID, a strong cash position ($851M) and major near‑term clinical catalysts (remlifanserin Phase II readout and trofinetide Japan Phase III). Headwinds include a temporary refill timing disruption that impacted Q1 NUPLAZID revenue timing, a sizable near‑term increase in SG&A (+35.3% YoY) to fund commercial expansion, ongoing regulatory uncertainty in Europe for trofinetide, and an R&D leadership transition. On balance, the positives (top‑line growth, product launches, reaffirmed guidance, pipeline catalysts and healthy cash) outweigh the challenges, which management describes largely as temporary or strategic investments.View all DE:DR6 earnings summariesDR6 Stock 12 Month Forecast
Average Price Target
€28.74
▲(30.16% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
PTC Therapeutics
―
Krystal Biotech
―
MoonLake Immunotherapeutics
―
―